- Home
- HIMS
as 10-29-2025 9:32am EST
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
Upcoming Earnings Alert:
Get ready for potential market movements as Hims & Hers Health Inc. HIMS prepares to release earnings report on 03 Nov 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 12.2B | IPO Year: | N/A |
| Target Price: | $37.20 | AVG Volume (30 days): | 29.6M |
| Analyst Decision: | Hold | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.79 | EPS Growth: | 866.21 |
| 52 Week Low/High: | $18.32 - $72.98 | Next Earning Date: | 11-03-2025 |
| Revenue: | $2,013,538,000 | Revenue Growth: | 88.69% |
| Revenue Growth (this year): | 61.73% | Revenue Growth (next year): | 19.39% |
Stock Insider Trading Activity of Hims & Hers Health Inc. (HIMS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Boughton Soleil | HIMS | Chief Legal Officer | Oct 27 '25 | Sell | $50.10 | 2,637 | $132,113.70 | 158,493 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Oct 17 '25 | Sell | $57.13 | 11,592 | $662,221.98 | 70,232 | |
| Dudum Andrew | HIMS | Chief Executive Officer | Oct 16 '25 | Sell | $62.94 | 175,661 | $11,029,998.77 | 92,523 | |
| Boughton Soleil | HIMS | Chief Legal Officer | Oct 13 '25 | Sell | $54.38 | 2,637 | $143,400.06 | 158,493 | |
| Chi Michael | HIMS | Chief Commercial Officer | Oct 10 '25 | Sell | $58.25 | 900 | $52,425.00 | 291,439 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Oct 3 '25 | Sell | $57.72 | 11,595 | $669,232.09 | 70,232 | |
| Chi Michael | HIMS | Chief Commercial Officer | Oct 1 '25 | Sell | $56.00 | 250 | $14,000.00 | 291,439 | |
| Boughton Soleil | HIMS | Chief Legal Officer | Sep 29 '25 | Sell | $58.79 | 2,637 | $155,029.23 | 158,493 | |
| Okupe Oluyemi | HIMS | Chief Financial Officer | Sep 29 '25 | Sell | $60.20 | 85,000 | $5,116,923.50 | 70,232 | |
| Chi Michael | HIMS | Chief Commercial Officer | Sep 24 '25 | Sell | $56.52 | 2,100 | $118,692.00 | 291,439 |
Latest Hims & Hers Health Inc. News
HIMS Breaking Stock News: Dive into HIMS Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Hims & Hers to Announce Third Quarter 2025 Financial Results on November 3, 2025
Zacks
19 days ago
Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know
StockStory
19 days ago
Why Hims & Hers Health (HIMS) Stock Is Nosediving
Investor's Business Daily
19 days ago
Taking Advantage Of Hims & Hers Stock Volatility
Yahoo Finance Video
20 days ago
How Hims & Hers founder Joe Spector turned 10 failures into $1B idea
Yahoo Finance Video
20 days ago
One founder's 3 rules for breaking into a complex market
Zacks
20 days ago
Hims & Hers Expands Personalized Care Access Via Telehealth Platform
Investor's Business Daily
20 days ago
Omada Health Stock Gets Relative Strength Rating Lift
Compare HIMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HIMS Hims & Hers Health Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.